Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success.

Desai A, Yan Y, Gerson SL.

Stem Cells Transl Med. 2018 Oct 17. doi: 10.1002/sctm.18-0123. [Epub ahead of print] Review.

2.

Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure.

Patel R, Zhang L, Desai A, Hoenerhoff MJ, Kennedy LH, Radivoyevitch T, Ban Y, Chen XS, Gerson SL, Welford SM.

Leukemia. 2018 Oct 1. doi: 10.1038/s41375-018-0269-8. [Epub ahead of print]

PMID:
30275527
3.

Advances in therapeutic targeting of the DNA damage response in cancer.

Desai A, Yan Y, Gerson SL.

DNA Repair (Amst). 2018 Jun - Jul;66-67:24-29. doi: 10.1016/j.dnarep.2018.04.004. Epub 2018 Apr 23. Review.

4.

Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy.

Liao X, Shen Y, Zhang R, Sugi K, Vasudevan NT, Alaiti MA, Sweet DR, Zhou L, Qing Y, Gerson SL, Fu C, Wynshaw-Boris A, Hu R, Schwartz MA, Fujioka H, Richardson B, Cameron MJ, Hayashi H, Stamler JS, Jain MK.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):E4661-E4669. doi: 10.1073/pnas.1720065115. Epub 2018 Apr 30.

PMID:
29712858
5.

MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation.

Patel R, Qing Y, Kennedy L, Yan Y, Pink J, Aguila B, Desai A, Gerson SL, Welford SM.

Stem Cells Transl Med. 2018 Apr 14. doi: 10.1002/sctm.17-0295. [Epub ahead of print]

6.

Patient Access to Academic Cancer Centers.

Gerson SL, Jensen RA.

J Med Syst. 2018 Mar 27;42(5):86. doi: 10.1007/s10916-018-0927-4. No abstract available.

PMID:
29589120
7.

A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.

Desai A, Zhang Y, Park Y, Dawson DM, Larusch GA, Kasturi L, Wald D, Ready JM, Gerson SL, Markowitz SD.

Haematologica. 2018 Jun;103(6):1054-1064. doi: 10.3324/haematol.2017.178376. Epub 2018 Feb 22.

8.

New Opportunities and Challenges to Defeat Cancer Stem Cells.

Ramos EK, Hoffmann AD, Gerson SL, Liu H.

Trends Cancer. 2017 Nov;3(11):780-796. doi: 10.1016/j.trecan.2017.08.007. Epub 2017 Sep 21. Review.

PMID:
29120754
9.

Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.

Yan Y, Qing Y, Pink JJ, Gerson SL.

Mol Cancer Res. 2018 Feb;16(2):212-221. doi: 10.1158/1541-7786.MCR-17-0215. Epub 2017 Nov 8.

PMID:
29117941
10.

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.

Oncotarget. 2017 Aug 9;8(45):79864-79875. doi: 10.18632/oncotarget.20094. eCollection 2017 Oct 3.

11.

Long-Term Deficits in Behavior Performances Caused by Low- and High-Linear Energy Transfer Radiation.

Patel R, Arakawa H, Radivoyevitch T, Gerson SL, Welford SM.

Radiat Res. 2017 Dec;188(6):672-680. doi: 10.1667/RR14795.1. Epub 2017 Sep 29.

PMID:
28961076
12.

New Advances and Challenges of Targeting Cancer Stem Cells.

Dashzeveg NK, Taftaf R, Ramos EK, Torre-Healy L, Chumakova A, Silver DJ, Alban TJ, Sinyuk M, Thiagarajan PS, Jarrar AM, Turaga SM, Saygin C, Mulkearns-Hubert E, Hitomi M, Rich JN, Gerson SL, Lathia JD, Liu H.

Cancer Res. 2017 Oct 1;77(19):5222-5227. doi: 10.1158/0008-5472.CAN-17-0054. Epub 2017 Sep 19.

13.

Mismatch repair deficient hematopoietic stem cells are preleukemic stem cells.

Qing Y, Gerson SL.

PLoS One. 2017 Aug 2;12(8):e0182175. doi: 10.1371/journal.pone.0182175. eCollection 2017.

14.

CCN3 Regulates Macrophage Foam Cell Formation and Atherosclerosis.

Shi H, Zhang C, Pasupuleti V, Hu X, Prosdocimo DA, Wu W, Qing Y, Wu S, Mohammad H, Gerson SL, Perbal B, Klenotic PA, Dong N, Lin Z.

Am J Pathol. 2017 Jun;187(6):1230-1237. doi: 10.1016/j.ajpath.2017.01.020.

15.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
16.

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

Tacastacas JD, Chan DV, Carlson S, Gerson SL, Dowlati A, Fu P, Lu K, Groft S, Rosenjack J, Honda K, McCormick TS, Cooper KD.

JAMA Dermatol. 2017 May 1;153(5):413-420. doi: 10.1001/jamadermatol.2016.5793.

17.

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20.

PMID:
28105889
18.

Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M.

Radiother Oncol. 2016 Nov;121(2):335-341. doi: 10.1016/j.radonc.2016.10.007. Epub 2016 Nov 9.

PMID:
27838149
19.

Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing.

Kenyon J, Nickel-Meester G, Qing Y, Santos-Guasch G, Drake E, PingfuFu, Sun S, Bai X, Wald D, Arts E, Gerson SL.

Int J Stem Cell Res Ther. 2016;3(2). pii: 031. Epub 2016 May 24.

20.

Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.

Yan Y, Han X, Qing Y, Condie AG, Gorityala S, Yang S, Xu Y, Zhang Y, Gerson SL.

Oncotarget. 2016 Sep 13;7(37):59299-59313. doi: 10.18632/oncotarget.11151.

21.

Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22.

PMID:
27443247
22.

Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.

Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ Jr.

J Natl Compr Canc Netw. 2016 Jul;14(7):837-47.

PMID:
27407124
23.

Matricellular protein CCN3 mitigates abdominal aortic aneurysm.

Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, Takemoto M, Yokote K, Moxon JV, Norman P, Rittié L, Kuivaniemi H, Atkins GB, Gerson SL, Shi GP, Golledge J, Dong N, Perbal B, Prosdocimo DA, Lin Z.

J Clin Invest. 2016 May 2;126(5):2012. doi: 10.1172/JCI87977. Epub 2016 May 2. No abstract available.

24.

Matricellular protein CCN3 mitigates abdominal aortic aneurysm.

Zhang C, van der Voort D, Shi H, Zhang R, Qing Y, Hiraoka S, Takemoto M, Yokote K, Moxon JV, Norman P, Rittié L, Kuivaniemi H, Atkins GB, Gerson SL, Shi GP, Golledge J, Dong N, Perbal B, Prosdocimo DA, Lin Z.

J Clin Invest. 2016 Apr 1;126(4):1282-99. doi: 10.1172/JCI82337. Epub 2016 Mar 14. Erratum in: J Clin Invest. 2016 May 2;126(5):2012.

25.

Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. Epub 2016 Mar 8.

PMID:
26953041
26.

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.

Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, Gao J, Anderson G, Liu L, Sarode V, Gerber DE, Burma S, DeBerardinis RJ, Gerson SL, Boothman DA.

Sci Rep. 2015 Nov 25;5:17066. doi: 10.1038/srep17066.

27.

Quantitative H2S-mediated protein sulfhydration reveals metabolic reprogramming during the integrated stress response.

Gao XH, Krokowski D, Guan BJ, Bederman I, Majumder M, Parisien M, Diatchenko L, Kabil O, Willard B, Banerjee R, Wang B, Bebek G, Evans CR, Fox PL, Gerson SL, Hoppel CL, Liu M, Arvan P, Hatzoglou M.

Elife. 2015 Nov 23;4:e10067. doi: 10.7554/eLife.10067.

28.

A Fluorescent Probe to Measure DNA Damage and Repair.

Condie AG, Yan Y, Gerson SL, Wang Y.

PLoS One. 2015 Aug 26;10(8):e0131330. doi: 10.1371/journal.pone.0131330. eCollection 2015.

29.

Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.

Caimi PF, William BM, Silva Rondon CH, Fu P, Cooper BW, Campagnaro EL, Gerson SL, Reese-Koc J, Fox R, Creger RJ, de Lima M, Lazarus HM.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1926-31. doi: 10.1016/j.bbmt.2015.06.007. Epub 2015 Jun 16.

30.

TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.

Zhang Y, Desai A, Yang SY, Bae KB, Antczak MI, Fink SP, Tiwari S, Willis JE, Williams NS, Dawson DM, Wald D, Chen WD, Wang Z, Kasturi L, Larusch GA, He L, Cominelli F, Di Martino L, Djuric Z, Milne GL, Chance M, Sanabria J, Dealwis C, Mikkola D, Naidoo J, Wei S, Tai HH, Gerson SL, Ready JM, Posner B, Willson JK, Markowitz SD.

Science. 2015 Jun 12;348(6240):aaa2340. doi: 10.1126/science.aaa2340.

31.

Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1529-1531. doi: 10.1016/j.bbmt.2015.04.022. Epub 2015 Apr 30.

32.

Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H.

Cancer Res. 2015 Mar 15;75(6):924-9. doi: 10.1158/0008-5472.CAN-14-3225. Epub 2015 Jan 20. Review.

33.

MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors.

Roth JC, Alberti MO, Ismail M, Lingas KT, Reese JS, Gerson SL.

Virus Res. 2015 Jan 22;196:170-80. doi: 10.1016/j.virusres.2014.11.027. Epub 2014 Dec 3.

34.

Uracil DNA glycosylase (UNG) loss enhances DNA double strand break formation in human cancer cells exposed to pemetrexed.

Weeks LD, Zentner GE, Scacheri PC, Gerson SL.

Cell Death Dis. 2014 Feb 6;5:e1045. doi: 10.1038/cddis.2013.477.

35.

CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells.

Desai A, Webb B, Gerson SL.

Radiother Oncol. 2014 Mar;110(3):538-45. doi: 10.1016/j.radonc.2013.10.040. Epub 2014 Jan 16.

36.
37.

Bcl2 overexpression rescues the hematopoietic stem cell defects in Ku70-deficient mice by restoration of quiescence.

Qing Y, Wang Z, Bunting KD, Gerson SL.

Blood. 2014 Feb 13;123(7):1002-11. doi: 10.1182/blood-2013-08-521716. Epub 2014 Jan 6.

38.

Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed.

Weeks LD, Fu P, Gerson SL.

Mol Cancer Ther. 2013 Oct;12(10):2248-60. doi: 10.1158/1535-7163.MCT-13-0172. Epub 2013 Jul 19.

39.

Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation.

Yu WM, Liu X, Shen J, Jovanovic O, Pohl EE, Gerson SL, Finkel T, Broxmeyer HE, Qu CK.

Cell Stem Cell. 2013 Jan 3;12(1):62-74. doi: 10.1016/j.stem.2012.11.022.

40.

Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice.

Zhou G, Hamik A, Nayak L, Tian H, Shi H, Lu Y, Sharma N, Liao X, Hale A, Boerboom L, Feaver RE, Gao H, Desai A, Schmaier A, Gerson SL, Wang Y, Atkins GB, Blackman BR, Simon DI, Jain MK.

J Clin Invest. 2012 Dec;122(12):4727-31. doi: 10.1172/JCI66056. Epub 2012 Nov 19.

41.

Two-photon fluorescent imaging of myelination in the spinal cord.

Condie AG, Gerson SL, Miller RH, Wang Y.

ChemMedChem. 2012 Dec;7(12):2194-203. doi: 10.1002/cmdc.201200343. Epub 2012 Nov 7.

PMID:
23136014
42.

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.

Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ.

Invest New Drugs. 2013 Jun;31(3):714-23. doi: 10.1007/s10637-012-9876-9. Epub 2012 Sep 29.

PMID:
23054206
43.

Cotransduction with MGMT and Ubiquitous or Erythroid-Specific GFP Lentiviruses Allows Enrichment of Dual-Positive Hematopoietic Progenitor Cells In Vivo.

Roth JC, Ismail M, Reese JS, Lingas KT, Ferrari G, Gerson SL.

ISRN Hematol. 2012;2012:212586. doi: 10.5402/2012/212586. Epub 2012 Jul 19.

44.

Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression.

Falahati R, Zhang J, Flebbe-Rehwaldt L, Shi Y, Gerson SL, Gaensler KM.

Mol Ther. 2012 Nov;20(11):2180-9. doi: 10.1038/mt.2012.136. Epub 2012 Aug 7.

45.

Development and validation of an LC-MS/MS method for pharmacokinetic study of methoxyamine in phase I clinical trial.

Yang S, Savvides P, Liu L, Gerson SL, Xu Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jul 15;901:25-33. doi: 10.1016/j.jchromb.2012.05.036. Epub 2012 Jun 6.

PMID:
22743337
46.

Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age.

Kenyon J, Fu P, Lingas K, Thomas E, Saurastri A, Santos Guasch G, Wald D, Gerson SL.

Blood. 2012 Oct 18;120(16):3229-36. doi: 10.1182/blood-2011-12-401950. Epub 2012 Jun 26.

47.

Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation.

Alberti MO, Roth JC, Ismail M, Tsuruta Y, Abraham E, Pereboeva L, Gerson SL, Curiel DT.

PLoS One. 2012;7(5):e37812. doi: 10.1371/journal.pone.0037812. Epub 2012 May 18.

48.

Production of human factor VIII-FL in 293T cells using the bicistronic MGMT(P140K)-retroviral vector.

Fontes AM, Melo FU, Greene LJ, Faça VM, Lin Y, Gerson SL, Covas DT.

Genet Mol Res. 2012 Mar 22;11(1):775-89. doi: 10.4238/2012.March.22.8.

49.

Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, Szabo SK, Fu P, Gilliam AC, Gerson SL, Remick SC, Cooper KD.

Arch Dermatol. 2012 May;148(5):613-20. doi: 10.1001/archdermatol.2011.2797.

50.

Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.

Bulgar AD, Weeks LD, Miao Y, Yang S, Xu Y, Guo C, Markowitz S, Oleinick N, Gerson SL, Liu L.

Cell Death Dis. 2012 Jan 12;3:e252. doi: 10.1038/cddis.2011.135.

Supplemental Content

Loading ...
Support Center